🇺🇸 FDA
Patent

US 9023795

Angiogenesis-inhibiting peptide and application thereof

granted A61KA61K38/00A61K38/179

Quick answer

US patent 9023795 (Angiogenesis-inhibiting peptide and application thereof) held by SHANGHAI FIRST PEOPLE'S HOSPITAL expires Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SHANGHAI FIRST PEOPLE'S HOSPITAL
Grant date
Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/00, A61K38/179, A61K38/18, A61K38/1891